Voltarol Emulgel Extra Strength 2% w/w Gel
Voltarol Emulgel Extra Strength 2% w/w Gel – eases joint and muscle pain and inflammation all day with twice daily application1
Provides up to 12 hours of relief from joint pain through an anti-inflammatory action.1
Contains diclofenac, a potent non-steroidal anti-inflammatory drug (NSAID) with effective analgesic and anti-inflammatory properties.2
Diclofenac gets deep into the joint area3
After topical administration, diclofenac is distributed to the subcutaneous tissues, muscle, synovial tissues and synovial fluid, the latter tissues typically being most likely to be driving joint pain.3 Its chemical properties support retention within the joint where it is needed, rather than the blood stream.3,4
Voltarol Emulgel Extra Strength 2% w/w Gel is specially formulated to help the anti-inflammatory ingredient get through the skin.5 It contains a permeation enhancer for increased delivery of diclofenac through the skin.5*
The deep penetration of Voltarol Emulgel Extra Strength 2% w/w Gel makes it suitable for the treatment of joint pain related to trauma of the tendons, ligaments, muscles and other joint tissues as well as localised soft-tissue rheumatism.
*Voltarol Emulgel Extra Strength 2% w/w Gel compared with Voltarol Emulgel P 1% w/w Gel (in vitro study) when measured over 24 hours.
Provides up to 12 hours of relief from joint pain1
Voltarol Emulgel Extra Strength 2% w/w Gel has proven clinical efficacy: in a study of acute ankle sprain, patients experienced a 65% reduction in pain from baseline after 4 days, with additional benefits in terms of reductions in swelling vs placebo.1
Voltarol Emulgel Extra Strength 2% w/w Gel provides all-day joint-pain relief, meaning convenient twice-daily application is all that is needed.1
Product information can be found at the bottom of the page
The lowest number-needed-to-treat (NNT) for Voltarol Gels* in a Cochrane Review of topical NSAIDs vs placebo6,7
A Cochrane Review of 61 studies of topical NSAIDs compared with placebo (>8000 patients) reported that Voltarol Gels* have the lowest NNT (1.8) of topical NSAIDs in acute musculoskeletal pain, including topical ibuprofen (3.9).6,7*†
This means that for every single patient you treat with Voltarol Gel over other topical NSAIDs, you have a better chance of giving them the significant pain relief that helps get them back on their feet and enjoying life again.6
*1.16% and 2.32% Voltarol Gel formulations included in the review.†vs topical ibuprofen, ketoprofen, benzydamine, piroxicam and indomethacin.
Low systemic absorption, for a lower risk of systemic side effects3,8
Voltarol Emulgel Extra Strength 2% w/w Gel has a low systemic exposure3,9 meaning a reduced risk of systemic side effects and drug–drug interactions.3
That includes a reduced systemic side-effect risk vs oral NSAIDs (e.g. gastrointestinal events).10,11*
*There is an increased risk of mild dermatological side effects (e.g. skin irritation) with topical diclofenac, but this is non-serious and reversible.
Nora needs to regain mobility by easing joint stiffness
Nora wakes up with joint pain and stiffness each morning and has difficulty climbing stairs but does not want this to control her life or her choices.
She already receives multiple oral medications and is concerned that adding more will increase her risk of side effects.
Nora tries to stay active by gardening and going for walks, but this can sometimes be a struggle.
She wants sustained relief from her pain so that she can do the things she enjoys.
Recommend Voltarol Emulgel Extra Strength 2% w/w Gel for your patients suffering with joint pain looking for long lasting relief.
Recommend Voltarol Emulgel Extra Strength 2% w/w Gel to your patients for relief of joint pain and inflammation all day long when applied twice daily
Voltarol Emulgel Extra Strength 2% w/w Gel
For patients who are looking for long-lasting relief from joint pain and inflammation, using a topical formulation.
Product Information: Please consult the Summary of Product Characteristics for full product information.
Voltarol Emulgel P 1% w/w Gel (diclofenac) and Voltarol Emulgel Extra Strength 2% w/w Gel (diclofenac). Indications: For the local symptomatic relief of pain and inflammation in trauma of tendons, ligaments, muscles and joints, localised forms of soft tissue rheumatism.
Dosage: Adults and adolescents 14 years and over: Voltarol Emulgel P 1% w/w Gel: 2g to 4g of gel, applied topically 3-4 times daily. Voltarol Emulgel Extra Strength 2% w/w Gel: 2g to 4g of gel, applied topically 2 times daily – morning and evening. Maximum recommended that treatment duration is 14 days. Patients should consult their doctor if the condition does not improve within 7 days or worsens.
Contraindications: Patients with or without chronic asthma in whom asthma, angioedema, urticaria or acute rhinitis are precipitated by aspirin or other non-steroidal anti-inflammatory agents. Hypersensitivity to diclofenac, acetylsalicylic acid or other non-steroidal anti-inflammatory drugs. Hypersensitivity to any other ingredient of the gel. Use in third trimester of pregnancy. Use in children and adolescents aged less than 14 years.
Warnings and precautions: Apply only to intact, non-diseased skin and not to skin wounds or open injuries. It should not be used with occlusion. It should not be allowed to come into contact with the eyes or mucous membranes and should never be taken by mouth. Application over extensive areas for prolonged periods or application in excess of recommended dosage may give rise to systemic effects. These include gastrointestinal disturbances and bleeding, irritability, fluid retention, rash, hepatitis, renal dysfunction, anaphylaxis and rarely blood dyscrasias, bronchospasm and erythema multiforme. Discontinue if rash develops. Use with caution in patients with a history of peptic ulcers, gastrointestinal bleeding, hepatic or renal insufficiency, or bleeding diathesis, or intestinal inflammation.
Pregnancy and lactation: The systemic concentration of diclofenac is lower after topical administration, compared to oral formulations. During the first and second trimester of pregnancy, diclofenac should not be given unless clearly necessary. Only use during lactation on the advice of a health professional. Contraindicated during the third trimester of pregnancy. Should not be applied on the breasts of nursing mothers, nor elsewhere on large areas of skin or for a prolonged period of time.
Side effects: Very rare: rash pustular, hypersensitivity (including urticaria), angioedema, asthma, photosensitivity reaction. Rare: Dermatitis bullous. Common: Dermatitis (including contact dermatitis), rash, erythema, eczema, pruritus.
Overdose: The low systemic absorption of topical diclofenac renders overdosage extremely unlikely.
MA Holder: GlaxoSmithKline Consumer Healthcare (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.
MA Number: Voltarol 1% w/w Gel: PA 678/140/2. Voltarol 2% w/w Gel: PA 678/140/3.
Legal Category: Pharmacy only.
Text revised: August 2020. Further information available on request.
The Voltarol gel range contains diclofenac diethylammonium. For relief of pain and inflammation. Always read the label/leaflet.